Update of a comparative analysis of cost minimization following the introduction of newly available intravenous iron therapies in hospital practice

Sunil Bhandari
Department of Renal Medicine, Hull and East Yorkshire Hospitals National Health Service Trust and Hull York Medical School, Kingston upon Hull, UK

Background: The clinical need to be able to administer high doses of intravenous iron conveniently as a rapid infusion has been addressed by the recent introduction of ferric carboxymaltose and subsequently iron isomaltoside 1000. Neither requires a test dose. The maximum dose of ferric carboxymaltose is 1000 mg. The maximum dose of iron isomaltoside 1000 is based on 20 mg/kg body weight without a specified ceiling dose, thereby increasing the scope of being able to achieve total iron repletion with a single infusion. This ability to give high doses of iron is important in the context of managing iron deficiency anemia, which is associated with a number of clinical conditions where demands for iron are high. It is also an important component of the strategy as an alternative to blood transfusion. Affordability is a key issue for health services. Recent price changes affecting iron sucrose and ferric carboxymaltose, plus modifications to the manufacturers’ prescribing information, have provoked this update.

Methods: This study is a comparative analysis of the costs of acquiring and administering the newly available intravenous iron formulations against standard treatments in the hospital setting. The costs include the medication, nursing costs, equipment, and patient transportation. Three dosage levels (600 mg, 1000 mg, and 1600 mg) are considered.

Results and conclusion: The traditional standard treatments, blood and iron sucrose, cost more than the alternative intravenous iron preparations across the dose spectrum and sensitivities. Low molecular weight iron dextran is the least expensive option at the 1600 mg dose level but has the caveat of a prolonged administration time and requirement for a test dose. At 600 mg and 1000 mg dose levels, both iron isomaltoside 1000 and ferric carboxymaltose are more economical than low molecular weight iron dextran. Iron isomaltoside 1000 is less expensive than ferric carboxymaltose at all dose levels. Newly available iron preparations appear to be clinically promising, cost effective, and practical alternatives to current standards of iron repletion.

Keywords: iron isomaltoside 1000, ferric carboxymaltose, iron deficiency anemia, single high dose, IV iron, cost minimization

Introduction
The ability to administer high doses of intravenous (IV) iron rapidly, without the need for a test dose, is an important development in the strategy for treating iron deficiency anemia (IDA). Ferric carboxymaltose was the first IV iron to be introduced to the UK that did not require a test dose. It can be given rapidly and administered up to 20 mg per kg body weight to a ceiling of 1000 mg per infusion.1 Iron isomaltoside 1000, whilst also administered rapidly, can be administered at up to 20 mg of iron per
kg of body weight. The absence of a specific dose ceiling for iron isomaltoside 1000 offers the opportunity to deliver very high doses (total doses) in a single administration. This may be of practical importance when calculating the treatment dose based on the Ganzoni formula that incorporates amounts for replenishing body iron stores. Doses for a number of disorders associated with IDA commonly require doses well in excess of 1000 mg.

A prerequisite for undertaking a cost minimization study is establishing similarity of outcome from the treatment options. Iron treatment may be considered a “basic physiological requirement” (a micronutrient). There is no evidence to indicate that the choice of IV iron formulation affects the physiological uptake or iron metabolism. Thus, whilst the literature provides evidence of efficacy (as measured by a range of measurable outcomes) for each of the IV iron treatment options (including blood), there are no comparative data to suggest a physiological difference in performance. It is also recognized that the legacy of adverse events (ADEs) experienced with Imferon® (Fisons, Ipswich, UK), a high molecular weight iron dextran formulation withdrawn from the European market almost two decades ago, has been superseded by subsequent treatments which are associated with low levels of similar ADEs and, as such, any costs associated with ADEs are likely to be similar across the treatment options.

The low level of ADEs associated with the two latest introductions (ferric carboxymaltose and iron isomaltoside 1000) is reflected in their approved modes of administration, as neither require the administration of a test dose. Patients receiving iron sucrose require a test dose prior to receiving their first dose. Those receiving low molecular weight iron dextran require a test dose at the time of each administration. The purpose of a test dose is to predose (challenge) with a small amount of iron (eg, 20–25 mg) of the chosen formulation followed by a period of observation to establish the likelihood of the formulation provoking an ADE. A test dose, followed by an observation period, extends the overall administration time and cost (nurse observation time). The arrival of two formulations where a test dose is explicitly excluded increases convenience (for both patients and health care professionals), reduces the overall administration time, and, furthermore, implicitly endorses the safety profile of the latest IV iron therapy options.

The original paper examining the comparative costs of IV iron therapy and standard blood transfusions was first published in March 2011. However, a subsequent modification in the price of two of the products included in the initial analysis reduced the validity of the results. This subsequent study reflects the changed product acquisition costs, the current price of blood in England and Wales, and the most recently published nursing costs.

**Background**

Blood is a declining resource. The safety associated with the receipt of a blood infusion has progressively improved over the last decade but there are recognized risks (and costs) associated with a blood transfusion. Strategies to reduce the risks have led to the imposition of restrictions on members of the population who can be blood donors. This has resulted in a decline in the volume of blood donated. Additionally, following the identification of blood-borne diseases in blood donated by UK donors (eg, prion-related diseases, including Creutzfeldt–Jakob disease), certain cohorts of the population are prevented from receiving blood and blood products prepared from blood donated in the UK.

The National Blood Transfusion Service has encouraged the conservation and appropriate use of blood and blood products. The policy of reducing inappropriate blood use is aimed at reducing both the intrinsic risks associated with blood and risks associated with the process of matching and administration.

These developments have been at a time when the importance, implications, and prevalence of IDA is being appreciated and associated with a broad range of clinical conditions and situations, for example, in:

- chronic kidney disease patients, including renal transplant patients with/without erythropoietin replacement therapy
- patients undergoing various modes of dialysis therapy
- anemia associated with pregnancy (pre/postpartum, following hemorrhage)
- anemia following “high blood loss” surgical procedures; eliminating or reducing the need for postsurgery transfusion (eg, orthopedics, colorectal surgery)
- the elderly (often iron deficient and/or anemic); especially prior to surgery where blood loss may be significant
- IDA associated with anemia of chronic disease
- chronic IDA (often presenting with acute symptoms)
- chronic occult blood loss (inflammatory bowel disease)
- anemia associated with cancer or the use of chemotherapy agents
- menorrhagia (heavy uterine bleeding)
- chronic heart failure.

In these situations, iron-store repletion provides the substrate for erythropoiesis, thereby restoring or improving
hemoglobin levels. This can commonly be achieved without the need for concomitant erythropoiesis-stimulating therapy.

Anemia of chronic disease may be a comorbidity associated with a number of chronic conditions (eg, rheumatoid arthritis, inflammatory bowel disease). In these conditions, where hepcidin blocks both the absorption of iron from the gastrointestinal tract and mobilization of stored iron, IV iron has been demonstrated to bypass these blocks.

Compared with oral iron, IV iron repletes iron stores more rapidly and can be given at high doses, as a total dose infusion, which improves compliance. Oral iron is associated with poor tolerance, poor compliance, and a high frequency of ADEs. It is poorly absorbed in patients with anemia of chronic disease and does not appear to bypass the immobilized iron stores. As such, its role as a useful source of iron supplementation is limited and its low cost often a “false economy.” However, in spite of such caveats, it is still commonly used as first-line iron supplementation for patients diagnosed with chronic kidney disease.

The administration of IV iron may be considered a more physiological method of addressing chronic IDA than a blood transfusion. A transfusion addresses the acute symptoms of anemia, but is a poor and expensive source of iron, whereas IV iron provides physiologically available iron for both erythropoiesis and replenishing iron stores.

The purpose of this paper is to examine the comparative cost to the health care economy of the IV iron supplementation options, including blood transfusion. The economic importance is driven by the need to optimize the use of services in the current challenging financial climate whilst serving the needs of patients and maintaining patient safety. In these circumstances, value for money and the overall relative cost of treatments are important when making policy prescribing decisions. Given that all options will achieve similar clinical responses, a cost minimization analysis was undertaken to determine the least expensive option overall.

### Methods

The costs of administering iron isomaltoside 1000 and ferric carboxymaltose are compared with the cost of administering a blood transfusion, iron sucrose, and low molecular weight iron dextran across a range of doses in a secondary care (hospital) setting. The cost model includes transportation, nursing, and equipment costs.

Initially, three matrix spreadsheets were established (one at each dose level) for the total costs of administering each of the options incorporating the sensitivity parameters (transport 10% and 20% of patients) and nurse grade (nurse team leader and 7 (nurse team manager) (ie, four total costs for each treatment option at the three dose levels).

From these, for each treatment option, and at each dose level, a mean cost was established with the maximum and minimum levels taken from their respective sensitivity calculations (Table 4). This allowed a comparison to be made and provided an indication of the level of robustness of the relative costs.

Cost differences between each of the three traditional treatments were calculated with reference to each of the two recently introduced formulations using the mean costs with the differences calculated as an absolute and percentage difference (Table 5).

Finally, a direct “head to head” comparison at each dose level was undertaken between the mean cost of ferric carboxymaltose and iron isomaltoside 1000 that provides the actual and percentage differences for each dose level (Table 6).

### Parameters for the revised cost model

**Standard treatment comparators**

Standard treatment will vary according to local practice and medical specialty. Traditionally, blood would have been the sole option in most of the indications/situations described. IV iron is used almost exclusively in

<table>
<thead>
<tr>
<th>Table 1 Comparative intravenous drip infusion regimens$^{1,2,18,19,27}$</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Product</strong></td>
</tr>
<tr>
<td>Dose limitation</td>
</tr>
<tr>
<td>Rate of administration</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Test dose</td>
</tr>
</tbody>
</table>

*Abbreviations: equ, equivalent; N/A, not applicable.*
hemodialysis patients, whereas, in other situations, IV iron is progressively replacing the practice of administering a blood transfusion.

As a standard treatment, blood is included as a comparator. Iron sucrose (considered a standard treatment) and low molecular weight iron dextran are also used as comparators.

**Dose levels**

The comparator doses were chosen to reflect clinical practice. Blood is transfused in multiples of “units.” Each unit may be considered to approximate 200 mg of elemental iron.

Iron doses are commonly calculated using the Ganzoni formula. It is not uncommon for an individual’s requirement to be up to 2000 mg or higher across the range of conditions associated with anemia.

For the purposes of this cost minimization modeling, three levels of administration were chosen (to provide a dose sensitivity matrix): 600 mg, 1000 mg, and 1600 mg. These allowed direct comparison with units of blood.

**Bioavailability and efficacy**

In preparing this cost minimization model, it was assumed that each of the IV iron preparations impact erythropoiesis and enter iron stores in a similar manner directly related to the dose administered. There is no evidence to suggest that incorporation of iron into reticulocytes, elevation of hemoglobin levels, and development of iron stores differs.

The administration of IV iron differs physiologically to the administration of a blood transfusion. Blood results in an immediate rise in hemoglobin level. Iron from a blood transfusion is then recycled as the erythrocytes expire, but the resulting elevation in iron stores and hemoglobin level are considered to be similar for the purposes of this study.

**ADEs**

In the cost modeling, no allowance was made for occurrence of ADEs. These are infrequent and similar for iron sucrose and low molecular weight iron dextran. The summaries of product characteristics for iron isomaltoside 1000 and ferric carboxymaltose indicate that ADEs associated with their use will be similar to those of currently available IV iron formulations.

Blood has higher levels of risk, both as a product per se and from the potential human error associated with compatibility testing and administration. However, no cost has been allocated to the treatment of these ADEs.

**Dose and rate of administration limitations**

In the cost modeling, the dose (including any constraints), rate of administration, and need for a test dose were taken from the manufacturers’ prescribing information (Tables 1–3).

The manufacturers’ instructions for undertaking a test dose were carefully incorporated into the modeling. For example, in the case of low molecular weight iron dextran, when administered for the first time, a 25 mg dose is given and the patient

---

**Table 2** Comparative intravenous injection regimens

<table>
<thead>
<tr>
<th>Product</th>
<th>Iron sucrose</th>
<th>Low molecular weight iron dextran</th>
<th>Iron isomaltoside 1000</th>
<th>Ferric carboxymaltose</th>
<th>Blood</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dose limitation</td>
<td>200 mg</td>
<td>200 mg</td>
<td>20 mg/kg</td>
<td>20 mg/kg max 1000 mg</td>
<td>N/A</td>
</tr>
<tr>
<td>Rate of administration</td>
<td>200 mg/5 mins</td>
<td>200 mg in 10 mins minimum – 20 mins maximum</td>
<td>0–10 mg/kg in 30 mins</td>
<td>1000 mg</td>
<td>N/A</td>
</tr>
<tr>
<td>Test dose</td>
<td>Required for first administration</td>
<td>Required at each administration</td>
<td>Not required</td>
<td>Not required</td>
<td>N/A</td>
</tr>
</tbody>
</table>

Abbreviation: N/A, not applicable.

---

**Table 3** Comparative high dose infusion regimens

<table>
<thead>
<tr>
<th>Product</th>
<th>Iron sucrose</th>
<th>Low molecular weight iron dextran</th>
<th>Iron isomaltoside 1000</th>
<th>Ferric carboxymaltose</th>
<th>Blood</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dose limitation</td>
<td>200 mg</td>
<td>20 mg/kg</td>
<td>20 mg/kg</td>
<td>20 mg/kg max 1000 mg</td>
<td>N/A</td>
</tr>
<tr>
<td>Rate of administration</td>
<td>200 mg/5 mins</td>
<td>200 mg in 10 mins minimum – 20 mins maximum</td>
<td>0–10 mg/kg in 30 mins</td>
<td>1000 mg</td>
<td>N/A</td>
</tr>
<tr>
<td>Test dose</td>
<td>Required for first administration</td>
<td>Required at each administration</td>
<td>Not required</td>
<td>Not required</td>
<td>N/A</td>
</tr>
</tbody>
</table>

Note: *Requires multiple administrations of 200 mg intravenous injections to deliver total dose. Abbreviation: N/A, not applicable.
observed for 45 minutes. The balance can then be administered if there are no ADEs. For the second and subsequent infusions, the first 25 mg of iron is infused over 15 minutes and, if there are no untoward events, the administration can be continued. When a total dose is administered, the patient should be observed for a further hour after the completion of the administration. For the administration of iron sucrose, a test dose is required only for the first administration to a patient.

For the purposes of this study, it was assumed that this was the second (or subsequent) administration to a patient of iron sucrose and low molecular weight iron dextran. For the specified range of doses, an observation period was included in the administration times for low molecular weight iron dextran (as indicated in the manufacturer’s prescribing information). Given the recommended dilution volume for preparing the infusion, it was assumed that the administration plus observation period would be similar at each dose level—that is, 6 hours in total. In this analysis, 10 minutes was allowed for setup time across the range of preparations.

### Transportation
This is an important factor when considering IV iron supplementation. Across the spectrum of patients with IDA, a proportion will be short of breath, perhaps with palpitations; will invariably be nonambulatory; and will be transported to hospital on a stretcher or in a wheelchair. Additionally, a number will be elderly, frail, and disabled. In the UK, ambulance services are paid for by the National Health Service. Two types of “transported” patient are considered: (1) those who are ambulatory, where the charge is GBP£12.00/single journey (GBP£24.00 return) and (2) those who are in a wheelchair or who require a stretcher where the charge for a single journey is GBP£48.00 single (GBP£96.00 return).

Across the spectrum of causes of IDA, it is difficult to establish the specific proportion of patients who require transportation and the ratio between ambulatory and nonambulatory patients. In this study, a sensitivity of 10% and 20% of patients requiring treatment is used. These percentages are to reflect transport requirements across the spectrum of patients with IDA.

### Table 4 Mean (with maximum and minimum range) comparative treatment costs for administering intravenous iron at three dose levels (600 mg, 1000 mg and, 1600 mg)

<table>
<thead>
<tr>
<th>Comparative costs, GBP£</th>
<th>Iron sucrose</th>
<th>Low molecular weight iron dextran</th>
<th>Iron isomaltoside 1000</th>
<th>Ferric carboxymaltose</th>
<th>Blood</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>600 mg iron</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean</td>
<td>261.61</td>
<td>221.19</td>
<td>170.21</td>
<td>173.23</td>
<td>449.80</td>
</tr>
<tr>
<td>Min</td>
<td>241.61</td>
<td>206.88</td>
<td>163.54</td>
<td>164.94</td>
<td>442.67</td>
</tr>
<tr>
<td>Max</td>
<td>281.61</td>
<td>235.49</td>
<td>176.87</td>
<td>181.52</td>
<td>456.92</td>
</tr>
<tr>
<td><strong>1000 mg iron</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean</td>
<td>436.02</td>
<td>253.07</td>
<td>231.71</td>
<td>249.63</td>
<td>737.55</td>
</tr>
<tr>
<td>Min</td>
<td>402.68</td>
<td>238.76</td>
<td>225.50</td>
<td>241.34</td>
<td>727.67</td>
</tr>
<tr>
<td>Max</td>
<td>469.35</td>
<td>267.37</td>
<td>237.92</td>
<td>257.92</td>
<td>747.42</td>
</tr>
<tr>
<td><strong>1600 mg iron</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean</td>
<td>697.63</td>
<td>300.89</td>
<td>333.41</td>
<td>404.86</td>
<td>1169.17</td>
</tr>
<tr>
<td>Min</td>
<td>644.29</td>
<td>286.58</td>
<td>327.20</td>
<td>394.27</td>
<td>1155.17</td>
</tr>
<tr>
<td>Max</td>
<td>750.96</td>
<td>315.19</td>
<td>339.62</td>
<td>415.44</td>
<td>1183.17</td>
</tr>
</tbody>
</table>

### Table 5 Relative cost position (mean) of iron isomaltoside 1000 and ferric carboxymaltose at three dose levels compared to standard treatments and blood

<table>
<thead>
<tr>
<th>Cost difference, GBP£ (%)</th>
<th>Iron isomaltoside 1000 vs iron sucrose</th>
<th>Iron isomaltoside 1000 vs low molecular weight iron dextran</th>
<th>Iron isomaltoside 1000 vs blood</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>600 mg dose</strong></td>
<td>–91.40 (–34.93%)</td>
<td>–50.98 (–23.05%)</td>
<td>–279.59 (–62.16%)</td>
</tr>
<tr>
<td><strong>1000 mg dose</strong></td>
<td>–204.31 (–46.86%)</td>
<td>–21.36 (–8.44%)</td>
<td>–505.84 (–68.58%)</td>
</tr>
<tr>
<td><strong>1600 mg dose</strong></td>
<td>–364.22 (–52.21%)</td>
<td>+32.52 (+10.81%)</td>
<td>–835.76 (–71.48%)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Ferric carboxymaltose vs iron sucrose</th>
<th>Ferric carboxymaltose vs low molecular weight iron dextran</th>
<th>Ferric carboxymaltose vs blood</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>600 mg dose</strong></td>
<td>–88.38 (–33.78%)</td>
<td>–47.96 (–21.68%)</td>
</tr>
<tr>
<td><strong>1000 mg dose</strong></td>
<td>–186.39 (–42.75%)</td>
<td>–3.44 (–1.36%)</td>
</tr>
<tr>
<td><strong>1600 mg dose</strong></td>
<td>–292.77 (–41.97%)</td>
<td>+103.97 (+34.55%)</td>
</tr>
</tbody>
</table>
Table 6  Relative cost position (mean) of iron isomaltoside 1000 versus ferric carboxymaltose at three dose levels of iron (600 mg, 1000 mg and, 1600 mg)

<table>
<thead>
<tr>
<th>Dose Level</th>
<th>Iron Isomaltoside Mean Cost (GBP£)</th>
<th>Ferric Carboxymaltose Mean Cost (GBP£)</th>
<th>Mean Cost Saving Iron Isomaltoside 1000 vs Ferric Carboxymaltose (GBP£)</th>
</tr>
</thead>
<tbody>
<tr>
<td>600 mg</td>
<td>170.21</td>
<td>173.23</td>
<td>3.02 (1.74%)</td>
</tr>
<tr>
<td>1000 mg</td>
<td>231.71</td>
<td>249.63</td>
<td>17.92 (7.18%)</td>
</tr>
<tr>
<td>1600 mg</td>
<td>333.41</td>
<td>404.86</td>
<td>71.45 (17.65%)</td>
</tr>
</tbody>
</table>

For example, few anemic pregnant women will require transport, but there will be a high demand for transportation by those undergoing dialysis or elderly persons undergoing surgery. It is assumed that those requiring transport will be equally split between those who are ambulatory and those who are nonambulatory (who require a stretcher or wheelchair).

Giving sets, cannula, and dressing
For the purpose of this analysis, unit costs reported by Bhandari and Naudeer were used. These were GBP£7.89 for a “giving set,” GBP£0.74 for one cannula, and GBP£0.54 for a standard dressing.

Nursing time
The costs for 1 hour of patient-contact nursing time in the UK at midband 6 and 7 have risen to GBP£70.00 (+4.5%) and GBP£81.00 (+5.2%), respectively, and reflect the latest figures published by the Personal Social Services Research Unit (2009/10). Nurse grades 6 (nurse team leader) and 7 (nurse team manager) are used to reflect the level of knowledge, experience, and responsibility required to run a nurse-led “anemia” service.

In the cost allocations, assumptions are made with regard to allocating time to represent multitasking (ie, not dedicating sole time to an individual patient during a 6-hour low molecular weight iron dextran total dose infusion administration). Thus, for a short administration (approximately 30 minutes) time, a nurse is likely to attend for the duration. For an infusion taking about 60 minutes it is assumed that the nurse will spend 50% of their time with the patient, whereas, for a prolonged infusion of low molecular weight iron dextran, a nurse is considered to spend 33% of their time with the patient. (During the test-dose phase and observation phase this may be 100%.) The differences in administration times are reflected in the nursing time and, therefore, nurse costs required for the administration of each treatment option at each dose level.

Cost of IV iron products
Recent price modifications are now used. For 200 mg iron, these are GBP£18.70 (+10%) for iron sucrose, GBP£15.94 for low molecular weight iron dextran, GBP£38.20 (−12.2%) for ferric carboxymaltose, and GBP£33.90 for iron isomaltoside 1000.

Cost of blood
The cost used in this modeling is now updated to that charged in England and Wales to NHS hospitals for 2010/11, which is GBP£125.00/unit (−6.37%) for red blood cells. (This does not include the cost of pretransfusion cross matching of a patient’s blood or error checking.)

Other costs
Expenditure considered minor or unlikely to be significant to the outcomes was excluded. This can be justified on the basis that, in any particular unit, the practice is likely to have a similar impact across the IV iron options. A cost deliberately omitted was that of the clinician. Whilst likely to be available during a transfusion, they would be undertaking other clinical/administrative duties, whereas a nurse would normally be responsible for administering the infusion and managing/monitoring the procedure. An example of a minor cost not included is that of the infusion fluid (normal saline), which costs GBP£0.70 per 250 mL.

Results
From Table 4, it is observed that both iron isomaltoside 1000 and ferric carboxymaltose are the lowest cost options when compared with iron sucrose and blood at each dose level and across all levels of sensitivity. When compared with low molecular weight iron dextran, both have a lower cost at the 600 mg and 1000 mg level, however, at the 1600 mg dose level, low molecular weight iron dextran offers a lower cost than both ferric carboxymaltose and iron isomaltoside 1000.

This same table indicates that low molecular weight iron dextran is less expensive than iron sucrose across the dose spectrum and across the sensitivity ranges. Blood is the highest cost option and this is without including the costs of cross matching.
The actual cost and percentage differences accruing from using either iron isomaltoside 1000 or ferric carboxymaltose compared with the current standard treatments are illustrated in Table 5. It is apparent throughout that greater savings are potentially realizable by adopting iron isomaltoside 1000 instead of ferric carboxymaltose and, on the single occasion that a traditional therapy is less expensive (ie, 1600 mg dose of low molecular weight iron dextran), the saving is GBP£103.97 compared with ferric carboxymaltose but only GBP£32.52 when compared with iron isomaltoside 1000.

A direct comparison of the cost of using the latest two entrants at the three dose levels is presented in Table 6. The potential expenditure savings from using iron isomaltoside 1000 at each dose level range from GBP£3.02 at the 600 mg dose level (1.74%), to GBP£71.45 at the 1600 mg dose level (17.65%).

**Discussion**

Blood continues to be used to treat IDA, in the absence of acute blood loss, associated with a number of conditions. This is against NHS Blood and Transplant policies to reduce blood use, which include the use of IV iron as an alternative to blood.\(^3\) There is, however, momentum gaining pace toward treating IDA with iron supplementation (normally with IV iron).

Renal medicine has been at the forefront of pioneering the use of IV iron. This practice historically developed following the introduction of iron sucrose. Iron sucrose can be administered in doses of up to 200 mg in a single administration and, as such, it was adopted in hemodialysis units. It is normally given to patients during one of their weekly hemodialysis sessions. This use of IV iron has resulted in a dramatic reduction in the requirement for blood transfusion.

The results of this updated cost minimization modeling (Tables 4 and 5) indicate that each of the IV iron options are less expensive than administering a blood transfusion at each iron repletion level and thereby may further encourage the consideration of iron as an alternative to blood in patients with IDA, especially in those diagnosed with chronic IDA.

Iron sucrose is well established as a standard treatment for IDA, however, its use is constrained by the maximum amount that can be given in a single administration. This is particularly pertinent when considering total iron repletion requirements. The Ganzoni formula is widely used to calculate these requirements.\(^3\) This formula embraces repletion of iron stores (frequently 500 mg of iron). The resulting dose calculation, depending on the weight of the patient, prevailing hemoglobin level, target hemoglobin level, and cause of IDA, may be well above 1000 mg and may exceed 2000 mg. To achieve repletion with iron sucrose would require multiple administrations of 200 mg doses, which is impractical and inconvenient. Furthermore, apart from blood, it is the least attractive option from a cost perspective across the dose range under consideration.

Since the withdrawal of Imferon\(^\circledR\) (high molecular weight iron dextran), low molecular weight iron dextran, available in the UK since the 1990s, has been at the forefront for clinicians wishing to administer large doses of iron at a single clinic visit. However, the prolonged infusion time may be considered a disadvantage both for the health service provider and the patient.

In this analysis, low molecular weight iron dextran has been shown to be less expensive than the standard treatments of blood and iron sucrose across the dose range. When compared to the more recently introduced options (ferric carboxymaltose and iron isomaltoside 1000) it is more expensive at the 600 mg and 1000 mg dose levels. At the 1600 mg dose level, ferric carboxymaltose is 34.6% more expensive to administer. Whilst iron isomaltoside 1000 is also more expensive, the difference is much less at 10.8% (GBP£32.52) and may perhaps be preferred (and justified) given the much reduced time required for administration, patient convenience, and potential increase in patient throughput (especially in the “payment by results” environment).

The direct comparison between iron isomaltoside 1000 and ferric carboxymaltose (Table 6) suggests that iron isomaltoside 1000 offers potential savings when compared with ferric carboxymaltose at all three dose levels but especially at the higher dose end of the spectrum.

In the modeling, key “drivers” are cost of medication, time for administration (affecting nurse resource), and transportation. The cost of the various iron formulations are National Health Service acquisition costs. The choice of available IV treatment options is limited to those included in this analysis.

This analysis has not embraced oral iron supplementation. It is acknowledged that oral iron has a significant role in preventing and treating IDA and has a much lower cost than either IV iron formulations or blood. However, the patient population that receive IV iron or blood is largely defined as those for whom oral iron is not appropriate, where oral iron has not been tolerated, has resulted in an unacceptable level of side effects, where compliance is poor, or where treatment has not achieved target iron parameters (ie, hemoglobin or ferritin levels).\(^1,2,18,19\) There is evidence to indicate that IV iron will achieve target parameters more quickly than oral
iron and, more importantly, when compared with oral iron, overcomes the “hepcidin block” affecting iron absorption and mobilization of iron stores in patients where IDA is associated with chronic conditions.23–25 The ability to give a total dose repletion rapidly, in a single infusion, overcomes compliance issues and is highly convenient for a number of patient types (eg, the elderly, in pregnancy). It may be justified on the basis of achieving target hemoglobin and ferritin levels more rapidly than oral iron – for example, prior to elective surgery – thereby reducing the incidence of cancellations due to poor anemic status.

Conclusion

Parenteral iron treatment has advanced significantly as a result of the introduction of ferric carboxymaltose and subsequently iron isomaltoside 1000. The scope for administering rapid single high doses of iron, without the need for a test dose, to address IDA associated with various clinical conditions, is a welcome development. This further enhances the prospect of using IV iron as an alternative to a blood transfusion for treating chronic IDA. This may be particularly important in the strategy of reducing blood use and reducing the incidence and volume of blood transfusions in the UK. It is particularly pertinent to note that this can be undertaken at a cost well below that of blood.

This updated analysis confirms that blood as a source of iron is expensive and is the least attractive option from a cost perspective. Iron sucrose, in addition to being able to be administered only in small 200 mg doses and requiring a test dose, is more expensive than the other available IV iron alternatives. Only at the highest dose level (1600 mg) does low molecular weight iron dextran offer cost savings worthy of any consideration compared with the two newest entrants.

Ferric carboxymaltose has a lower cost than iron sucrose and blood across the dose range; is only noticeably more expensive than low molecular weight iron dextran at the 1600 mg level, where the cost difference has to be balanced against administration time, convenience, and patient throughput. It is, however, more expensive than iron isomaltoside 1000 at each dose level (progressively, GBP£3.02 at 600 mg, GBP£17.92 at 1000 mg, and GBP£71.45 at the 1600 mg dose levels).

Likewise, iron isomaltoside 1000 has a lower cost than iron sucrose and blood across the dose range; it compares favorably with low molecular weight iron dextran at the 600 mg and 1000 mg dose levels but is marginally more expensive at the 1600 mg level. Cost savings compared to ferric carboxymaltose prevail across the dose range but are less pronounced than previously published following this product’s price reduction.

This analysis of the relative holistic cost of administering the treatment options endeavors to more closely reflect the “real world” situation when making prescribing policy decisions associated with the treatment of IDA.

Disclosure

The author reports no conflicts of interest in this work.

References


